Disease activity measures for rheumatoid arthritis clinical trials
Kondo, H.
Ryumachi 37(6): 825-831
1997
ISSN/ISBN: 0300-9157 PMID: 9492571 Document Number: 482637
Document emailed within 1 workday
Related Documents
Lassere, M.N.; van der Heijde, D.; Johnson, K.R.; Boers, M.; Edmonds, J. 2001: Reliability of measures of disease activity and disease damage in rheumatoid arthritis: implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials Journal of Rheumatology 28(4): 892-903van der Heide, A.; Jacobs, J.W.; Schenk, Y.; Bijlsma, J.W. 1994: Endpoint measures in rheumatoid arthritis clinical trials: group summary and individual patient analysis Journal of Rheumatology 21(12): 2195-2199
Salaffi, F.; Migliore, A.; Scarpellini, M.; Corsaro, S.M.; Laganà, B.; Mozzani, F.; Varcasia, G.; Pusceddu, M.; Pomponio, G.; Romeo, N.; Maier, A.; Foti, R.; Scarpa, R.; Gasparini, S.; Bombardieri, S. 2010: Psychometric properties of an index of three patient reported outcome (PRO) measures, termed the CLinical ARthritis Activity (PRO-CLARA) in patients with rheumatoid arthritis. The NEW INDICES study Clinical and experimental rheumatology 28(2): 186-200
Baldini, C.; Delle Sedie, A.; Bombardieri, S. 2005: From clinical trials to the bedside: how can we treat patients with rheumatoid arthritis and concurrent morbidities who are generally excluded from randomised controlled clinical trials? Clinical and Experimental Rheumatology 23(6): 893-904
Chen, J.R.; Takahashi, M.; Suzuki, M.; Kushida, K.; Miyamoto, S.; Inoue, T. 1998: Pentosidine in synovial fluid in osteoarthritis and rheumatoid arthritis: relationship with disease activity in rheumatoid arthritis Journal of Rheumatology 25(12): 2440-2444
Shaver, T.S.; Anderson, J.D.; Weidensaul, D.N.; Shahouri, S.H.; Shahouri, S.S.; Busch, R.E.; Mikuls, T.R.; Michaud, K.; Wolfe, F. 2008: The problem of rheumatoid arthritis disease activity and remission in clinical practice Journal of Rheumatology 35(6): 1015-1022
Bellamy, N.; Anastassiades, T.P.; Buchanan, W.W.; Davis, P.; Lee, P.; McCain, G.A.; Wells, G.A.; Campbell, J. 1991: Rheumatoid arthritis antirheumatic drug trials. II. Tables for calculating sample size for clinical trials of antirheumatic drugs Journal of Rheumatology 18(12): 1901-1907
Brun, J.G.; Haga, H.J.; Bøe, E.; Kallay, I.; Lekven, C.; Berntzen, H.B.; Fagerhol, M.K. 1992: Calprotectin in patients with rheumatoid arthritis: relation to clinical and laboratory variables of disease activity Journal of Rheumatology 19(6): 859-862
Ichikawa, Y.; Yamada, C.; Horiki, T.; Hoshina, Y.; Uchiyama, M. 1998: Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis Clinical and Experimental Rheumatology 16(5): 533-540
Koehn, C.L. 2005: The role of ethnicity in willingness to participate in rheumatoid arthritis clinical trials Journal of Rheumatology 32(12): 2283-2284
Strand, V.; Scott, D.L.; Panayi, G.S. 1994: Evaluating biologic agents in rheumatoid arthritis: a framework for clinical trials Journal of Rheumatology 21(8): 1390-1392
Lee, S.J.; Lenert, L.; Weisman, S.; Kavanaugh, A. 2005: Factors affecting rheumatoid arthritis patients' decisions to participate in clinical trials Journal of Rheumatology 32(12): 2317-2325
Rooney, M.; Whelan, A.; Feighery, C.; Bresnihan, B. 1989: The immunohistologic features of synovitis, disease activity and in vitro IgM rheumatoid factor synthesis by blood mononuclear cells in rheumatoid arthritis Journal of Rheumatology 16(4): 459-467
Pham, B.; Cranney, A.; Boers, M.; Verhoeven, A.C.; Wells, G.; Tugwell, P. 1999: Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials Journal of Rheumatology 26(3): 712-716
Mäkinen, H.; Hannonen, P.; Sokka, T. 2006: Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission Clinical and Experimental Rheumatology 24(6 Suppl 43: S
Strand, V. 2004: Longer term benefits of treating rheumatoid arthritis: assessment of radiographic damage and physical function in clinical trials Clinical and Experimental Rheumatology 22(5 Suppl 35: S57-S64
Veehof, M.M.; ten Klooster, P.M.; Taal, E.; van Riel, P.L.C.M.; van de Laar, M.A.F.J. 2008: Comparison of internal and external responsiveness of the generic Medical Outcome Study Short Form-36 (SF-36) with disease-specific measures in rheumatoid arthritis Journal of Rheumatology 35(4): 610-617
Uemura, Y.; Hayashi, H.; Takahashi, T.; Saitho, T.; Umeda, R.; Ichise, Y.; Sendo, S.; Tsuji, G.; Kumagai, S. 2015: MMP-3 as a Biomarker of Disease Activity of Rheumatoid Arthritis Rinsho Byori. Japanese Journal of Clinical Pathology 63(12): 1357-1364
Mäkinen, H.; Kautiainen, H.; Hannonen, P.; Sokka, T. 2008: A new disease activity index for rheumatoid arthritis: Mean Overall Index for Rheumatoid Arthritis (MOI-RA) Journal of Rheumatology 35(8): 1522-1527
Hanly, J.G.; Mosher, D.; Sutton, E.; Weerasinghe, S.; Theriault, D. 1996: Self-assessment of disease activity by patients with rheumatoid arthritis Journal of Rheumatology 23(9): 1531-1538